RCMI Coordinating Center (RCMI CC) Header Logo

Oral fluorouracil vs vinorelbine plus cisplatin as adjuvant chemotherapy for stage II-IIIA non-small cell lung cancer: Propensity score-matched and instrumental variable analyses.

Urushiyama H, Jo T, Yasunaga H, Michihata N, Matsui H, Hasegawa W, Takeshima H, Sakamoto Y, Hiraishi Y, Mitani A, Fushimi K, Nagase T, Yamauchi Y. Oral fluorouracil vs vinorelbine plus cisplatin as adjuvant chemotherapy for stage II-IIIA non-small cell lung cancer: Propensity score-matched and instrumental variable analyses. Cancer Med. 2018 10; 7(10):4863-4869.

View in: PubMed

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support